Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Research Article

TPD52 is a Potential Prognostic Biomarker and Correlated with Immune Infiltration: A Pan-cancer Analysis

Author(s): Lu Miao*, Li Jing, Buze Chen, Tian Zeng and Youguo Chen

Volume 24, Issue 11, 2024

Published on: 16 October, 2023

Page: [1413 - 1425] Pages: 13

DOI: 10.2174/0115665240260252230919054858

Price: $65

conference banner
Abstract

Background: Some tumors have a poor prognosis regarding TPD52 (tumor protein D52). This study aims to explore TPD52's role in the cancer process from a pan-cancer perspective.

Methods: A pan-cancer analysis was conducted to investigate how TPD52 may be involved in cancer as well as its association with prognosis.

Results: A variety of human cancers express TPD52 abnormally and correlate with clinical stage. There was a significant association between low expression of TPD52 and poor survival in BRCA, KIRP, LAML, LIHC, UCEC, and UVM. TPD52 alterations were most frequently amplified in pan-cancer. The co-occurrence of 10 genes alterations was found in the TPD52 altered group. There was a significant association between TPD52 expression and MSI in four cancer types and TMB in twelve cancer types. There was a significant correlation between TPD52 expression and immunerelated cell infiltration. A significant correlation was found between TPD52 expression in many tumor types and 8 immune checkpoint genes. There were signaling pathways involved in pan-cancer caused by TPD52, including endocytosis, Fc gamma Rmediated phagocytosis, and so on. TPD52 may be involved in chemotherapy and chemoresistance.

Conclusion: The TPD52 gene may be important for human cancer treatment.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy